Marsha Fanucci - 08 Jun 2021 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Director
Signature
/s/ Gerald E. Quirk, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
08 Jun 2021
Transactions value $
$0
Form type
4
Filing time
10 Jun 2021, 17:28:20 UTC
Next filing
21 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +17.5K $0.00 17.5K 08 Jun 2021 Common Stock 17.5K $6.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.